Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $10.1 million.

  • Kiniksa Pharmaceuticals International's Share-based Compensation rose 2961.92% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year increase of 1623.57%. This contributed to the annual value of $30.7 million for FY2024, which is 1305.39% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Share-based Compensation stood at $10.1 million for Q3 2025, which was up 2961.92% from $8.9 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Share-based Compensation ranged from a high of $10.1 million in Q3 2025 and a low of $5.7 million during Q2 2021
  • Its 5-year average for Share-based Compensation is $7.1 million, with a median of $6.8 million in 2023.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Share-based Compensation crashed by 1536.63% in 2022 and then soared by 2961.92% in 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Share-based Compensation (Quarter) stood at $6.1 million in 2021, then increased by 3.93% to $6.4 million in 2022, then increased by 21.99% to $7.8 million in 2023, then increased by 6.75% to $8.3 million in 2024, then increased by 22.25% to $10.1 million in 2025.
  • Its Share-based Compensation stands at $10.1 million for Q3 2025, versus $8.9 million for Q2 2025 and $7.7 million for Q1 2025.